{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:05:20Z","timestamp":1776276320416,"version":"3.50.1"},"reference-count":41,"publisher":"Tohoku University Medical Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2018]]},"DOI":"10.1620\/tjem.244.263","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T22:27:32Z","timestamp":1521757652000},"page":"263-270","source":"Crossref","is-referenced-by-count":27,"title":["Interleukin-35 as a New Biomarker of Renal Involvement in Lupus Nephritis Patients"],"prefix":"10.1620","volume":"244","author":[{"given":"Di","family":"He","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Aggarwal, A., Gupta, R., Negi, V.S., Rajasekhar, L., Misra, R., Singh, P., Chaturvedi, V. &amp; Sinha, S. (2017) Urinary haptoglobin, alpha-1 anti-chymotrypsin and retinol binding protein identified by proteomics as potential biomarkers for lupus nephritis. <i>Clin. Exp. Immunol.<\/i>, 188, 254-262.","DOI":"10.1111\/cei.12930"},{"key":"2","unstructured":"Bonelli, M., Savitskaya, A., Steiner, C.W., Rath, E., Smolen, J.S. &amp; Scheinecker, C. (2009) Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. <i>J. Immunol.<\/i>, 182, 1689-1695."},{"key":"3","unstructured":"Bonelli, M., von Dalwigk, K., Savitskaya, A., Smolen, J.S. &amp; Scheinecker, C. (2008) Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis. <i>Ann. Rheum. Dis.<\/i>, 67, 664-671."},{"key":"4","doi-asserted-by":"crossref","unstructured":"Cai, Z., Wong, C.K., Dong, J., Chu, M., Jiao, D., Kam, N.W., Lam, C.W. &amp; Tam, L.S. (2015a) Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)\/lpr mice. <i>Clin. Exp. Immunol.<\/i>, 181, 253-266.","DOI":"10.1111\/cei.12639"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Cai, Z., Wong, C.K., Kam, N.W., Dong, J., Jiao, D., Chu, M., Lam, C.W. &amp; Tam, L.S. (2015b) Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus. <i>Lupus<\/i>, 24, 1257-1266.","DOI":"10.1177\/0961203315585815"},{"key":"6","unstructured":"Cao, D., Malmstrom, V., Baecher-Allan, C., Hafler, D., Klareskog, L. &amp; Trollmo, C. (2003) Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. <i>Eur. J. Immunol.<\/i>, 33, 215-223."},{"key":"7","doi-asserted-by":"crossref","unstructured":"Cockcroft, D.W. &amp; Gault, M.H. (1976) Prediction of creatinine clearance from serum creatinine. <i>Nephron<\/i>, 16, 31-41.","DOI":"10.1159\/000180580"},{"key":"8","unstructured":"Collison, L.W., Chaturvedi, V., Henderson, A.L., Giacomin, P.R., Guy, C., Bankoti, J., Finkelstein, D., Forbes, K., Workman, C.J., Brown, S.A., Rehg, J.E., Jones, M.L., Ni, H.T., Artis, D., Turk, M.J. &amp; Vignali, D.A. (2010) IL-35-mediated induction of a potent regulatory T cell population. <i>Nat. Immunol.<\/i>, 11, 1093-1101."},{"key":"9","unstructured":"Collison, L.W., Delgoffe, G.M., Guy, C.S., Vignali, K.M., Chaturvedi, V., Fairweather, D., Satoskar, A.R., Garcia, K.C., Hunter, C.A., Drake, C.G., Murray, P.J. &amp; Vignali, D.A. (2012) The composition and signaling of the IL-35 receptor are unconventional. <i>Nat. Immunol.<\/i>, 13, 290-299."},{"key":"10","doi-asserted-by":"crossref","unstructured":"Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., Cross, R., Sehy, D., Blumberg, R.S. &amp; Vignali, D.A. (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. <i>Nature<\/i>, 450, 566-569.","DOI":"10.1038\/nature06306"},{"key":"11","unstructured":"Egwuagu, C.E., Yu, C.R., Sun, L. &amp; Wang, R. (2015) Interleukin 35: critical regulator of immunity and lymphocyte-mediated diseases. <i>Cytokine Growth Factor Rev.<\/i>, 26, 587-593."},{"key":"12","unstructured":"Gladman, D.D., Ibanez, D. &amp; Urowitz, M.B. (2002) Systemic lupus erythematosus disease activity index 2000. <i>J. Rheumatol.<\/i>, 29, 288-291."},{"key":"13","unstructured":"Goilav, B., Putterman, C. &amp; Rubinstein, T.B. (2015) Biomarkers for kidney involvement in pediatric lupus. <i>Biomark. Med.<\/i>, 9, 529-543."},{"key":"14","doi-asserted-by":"crossref","unstructured":"Guan, S.Y., Leng, R.X., Khan, M.I., Qureshi, H., Li, X.P., Ye, D.Q. &amp; Pan, H.F. (2017) Interleukin-35: a potential therapeutic agent for autoimmune diseases. <i>Inflammation<\/i>, 40, 303-310.","DOI":"10.1007\/s10753-016-0453-9"},{"key":"15","unstructured":"Hochberg, M.C. (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. <i>Arthritis Rheum.<\/i>, 40, 1725."},{"key":"16","doi-asserted-by":"crossref","unstructured":"Hu, L., Chen, C., Zhang, J., Wu, K., Zhang, X., Liu, H. &amp; Hou, J. (2017) IL-35 pretreatment alleviates lipopolysaccharide-induced acute kidney injury in mice by inhibiting NF-kappaB activation. <i>Inflammation<\/i>, 40, 1393-1400.","DOI":"10.1007\/s10753-017-0582-9"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Kochetkova, I., Golden, S., Holderness, K., Callis, G. &amp; Pascual, D.W. (2010) IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. <i>J. Immunol.<\/i>, 184, 7144-7153.","DOI":"10.4049\/jimmunol.0902739"},{"key":"18","unstructured":"Koutsokeras, T. &amp; Healy, T. (2014) Systemic lupus erythematosus and lupus nephritis. <i>Nat. Rev. Drug Discov.<\/i>, 13, 173-174."},{"key":"19","unstructured":"Liao, X., Ren, J., Reihl, A., Pirapakaran, T., Sreekumar, B., Cecere, T.E., Reilly, C.M. &amp; Luo, X.M. (2017) Renal-infiltrating CD11c+ cells are pathogenic in murine lupus nephritis through promoting CD4+ T cell responses. <i>Clin. Exp. Immunol.<\/i>, 190, 187-200."},{"key":"20","doi-asserted-by":"crossref","unstructured":"Lin, Y.L., Shieh, C.C. &amp; Wang, J.Y. (2008) The functional insufficiency of human CD4+CD25 high T-regulatory cells in allergic asthma is subjected to TNF-alpha modulation. <i>Allergy<\/i>, 63, 67-74.","DOI":"10.1111\/j.1398-9995.2007.01526.x"},{"key":"21","unstructured":"Munroe, M.E., Vista, E.S., Merrill, J.T., Guthridge, J.M., Roberts, V.C. &amp; James, J.A. (2017) Pathways of impending disease flare in African-American systemic lupus erythematosus patients. <i>J. Autoimmun.<\/i>, 78, 70-78."},{"key":"22","unstructured":"Niedbala, W., Wei, X.Q., Cai, B., Hueber, A.J., Leung, B.P., McInnes, I.B. &amp; Liew, F.Y. (2007) IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. <i>Eur. J. Immunol.<\/i>, 37, 3021-3029."},{"key":"23","doi-asserted-by":"crossref","unstructured":"Okada, K., Fujimura, T., Kikuchi, T., Aino, M., Kamiya, Y., Izawa, A., Iwamura, Y., Goto, H., Okabe, I., Miyake, E., Hasegawa, Y., Mogi, M. &amp; Mitani, A. (2017) Effect of interleukin (IL)-35 on IL-17 expression and production by human CD4+ T cells. <i>PeerJ<\/i>, 5, e2999.","DOI":"10.7717\/peerj.2999"},{"key":"24","unstructured":"Ouyang, H., Shi, Y.B., Liu, Z.C., Wang, Z., Feng, S., Kong, S.M. &amp; Lu, Y. (2014) Decreased interleukin 35 and CD4+EBI3+ T cells in patients with active systemic lupus erythematosus. <i>Am. J. Med. Sci.<\/i>, 348, 156-161."},{"key":"25","doi-asserted-by":"crossref","unstructured":"Qiu, F., Song, L., Yang, N. &amp; Li, X. (2013) Glucocorticoid downregulates expression of IL-12 family cytokines in systemic lupus erythematosus patients. <i>Lupus<\/i>, 22, 1011-1016.","DOI":"10.1177\/0961203313498799"},{"key":"26","unstructured":"Rahman, A. &amp; Isenberg, D.A. (2008) Systemic lupus erythematosus. <i>N. Engl. J. Med.<\/i>, 358, 929-939."},{"key":"27","doi-asserted-by":"crossref","unstructured":"Rahman, P., Gladman, D.D., Ibanez, D. &amp; Urowitz, M.B. (2001) Significance of isolated hematuria and isolated pyuria in systemic lupus erythematosus. <i>Lupus<\/i>, 10, 418-423.","DOI":"10.1191\/096120301678646164"},{"key":"28","unstructured":"Sawant, D.V., Hamilton, K. &amp; Vignali, D.A. (2015) Interleukin-35: expanding its job profile. <i>J. Interferon Cytokine Res.<\/i>, 35, 499-512."},{"key":"29","unstructured":"Schetz, M., Gunst, J. &amp; Van den Berghe, G. (2014) The impact of using estimated GFR versus creatinine clearance on the evaluation of recovery from acute kidney injury in the ICU. <i>Intensive Care Med.<\/i>, 40, 1709-1717."},{"key":"30","unstructured":"Silva, M.V., Moscoso Solorzano, G., Nishida, S.K. &amp; Kirsztajn, G.M. (2011) Are serum cystatin C levels influenced by steroid doses in lupus nephritis patients? <i>J. Bras. Nefrol.<\/i>, 33, 306-312."},{"key":"31","unstructured":"Stamenkovic, I., Favre, H., Donath, A., Assimacopoulos, A. &amp; Chatelanat, F. (1986) Renal biopsy in SLE irrespective of clinical findings: long-term follow-up. <i>Clin. Nephrol.<\/i>, 26, 109-115."},{"key":"32","doi-asserted-by":"crossref","unstructured":"Sule, S.D., Moodalbail, D.G., Burnham, J., Fivush, B. &amp; Furth, S.L. (2015) Predictors of kidney disease in a cohort of pediatric patients with lupus. <i>Lupus<\/i>, 24, 862-868.","DOI":"10.1177\/0961203315570162"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Tomcik, M., Zerr, P., Palumbo-Zerr, K., Storkanova, H., Hulejova, H., Spiritovic, M., Kodet, O., Stork, J., Becvar, R., Vencovsky, J., Pavelka, K., Filkova, M., Distler, J.H. &amp; Senolt, L. (2015) Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. <i>Rheumatology <\/i>(<i>Oxford<\/i>), 54, 2273-2282.","DOI":"10.1093\/rheumatology\/kev260"},{"key":"34","unstructured":"Tselios, K., Sarantopoulos, A., Gkougkourelas, I. &amp; Boura, P. (2014) CD4+CD25highFOXP3+ T regulatory cells as a biomarker of disease activity in systemic lupus erythematosus: a prospective study. <i>Clin. Exp. Rheumatol.<\/i>, 32, 630-639."},{"key":"35","unstructured":"Valencia, X., Yarboro, C., Illei, G. &amp; Lipsky, P.E. (2007) Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. <i>J. Immunol.<\/i>, 178, 2579-2588."},{"key":"36","unstructured":"Vignali, D.A., Collison, L.W. &amp; Workman, C.J. (2008) How regulatory T cells work. <i>Nat. Rev. Immunol.<\/i>, 8, 523-532."},{"key":"37","doi-asserted-by":"crossref","unstructured":"Waldman, M. &amp; Madaio, M.P. (2005) Pathogenic autoantibodies in lupus nephritis. <i>Lupus<\/i>, 14, 19-24.","DOI":"10.1191\/0961203305lu2054oa"},{"key":"38","unstructured":"Weening, J.J., D\u2019Agati, V.D., Schwartz, M.M., Seshan, S.V., Alpers, C.E., Appel, G.B., Balow, J.E., Bruijn, J.A., Cook, T., Ferrario, F., Fogo, A.B., Ginzler, E.M., Hebert, L., Hill, G., Hill, P., et al. (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. <i>J. Am. Soc. Nephrol.<\/i>, 15, 241-250."},{"key":"39","doi-asserted-by":"crossref","unstructured":"Wong, C.K., Lit, L.C., Tam, L.S., Li, E.K., Wong, P.T. &amp; Lam, C.W. (2008) Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. <i>Clin. Immunol.<\/i>, 127, 385-393.","DOI":"10.1016\/j.clim.2008.01.019"},{"key":"40","unstructured":"Yin, L., Ge, Y., Yang, H., Peng, Q., Lu, X., Zhang, Y. &amp; Wang, G. (2016) The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis. <i>Clin. Rheumatol.<\/i>, 35, 2715-2721."},{"key":"41","doi-asserted-by":"crossref","unstructured":"Yu, W., Ge, M., Lu, S., Shi, J., Li, X., Zhang, J., Wang, M., Huang, J., Shao, Y., Huang, Z., Zhang, J., Nie, N. &amp; Zheng, Y. (2015) Anti-inflammatory effects of interleukin-35 in acquired aplastic anemia. <i>Cytokine<\/i>, 76, 409-416.","DOI":"10.1016\/j.cyto.2015.08.004"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/244\/4\/244_263\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T19:34:37Z","timestamp":1660678477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/244\/4\/244_263\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.244.263","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}